Structural biology is shifting from predicting protein shapes to uncovering broader organizational rules AI tools like AlphaFold have made large-scale protein structure data far more accessible Researchers are increasingly exploring recurring patterns in amino acid organization across proteins Distributed and … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech, Science, Spain, Technology, United Kingdom
Tagged AlphaFold, amino acid clustering, Bioinformatics, CASP14, citizen science, computational biology, DeepMind, distributed computing, drug discovery, EteRNA, EU-Citizen Science, Folding@home, Foldit, Francisco Javier Lobo Cabrera, José Antonio Prado-Bassas, María Ángeles García-Rosado Delgado, molecular modeling, Mosaic Q, Open Science, protein architecture, protein data, protein engineering, protein structure, Proteins Mosaic Q, Rosetta@home, SciStarter, structural biology, structural patterns, synthetic biology, University of Washington
(IN BRIEF) Gerresheimer has launched Gx InMonit, a smart add-on device for autoinjectors, along with Gx AdheraLink, an AI-driven messaging solution, to improve patient adherence to home-based injection therapies. The system guides patients through the injection process, captures real-time data, … Read the full press release
Posted in Artificial Intelligence (AI), Germany, Healthcare, Pharma & Biotech, Technology
Tagged AI messaging, autoinjector, Centor, digital health, Gerresheimer, Gerresheimer Introduces Smart Injection Support Ecosystem to Improve Patient Adherence and Therapy Outcomes, Gerresheimer Launches Gx InMonit and AI Driven AdheraLink to Transform Home Based Injection Therapy Management, Gx AdheraLink, Gx Inbeneo, Gx InMonit, Healthcare Innovation, home therapy, Mithun Ratnakumar, NFC, patient adherence, pharmaceutical technology, remote monitoring, RxCap
A new citizen-science project is investigating a possible universal structural pattern in protein 3D architecture The pattern involves amino acids clustering by chemical type into mosaic-like arrangements Findings are based on analysis of over 160,000 protein structures and computational simulations … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged 3D protein structure, 3D protein-structure snapshots, 3D structure of proteins, a citizen-science project, amino acid clustering, amino acids, Bioinformatics, biology, biomolecules, biotechnology, citizen science, citizen-science platforms, collaborative science, computational biology, crowdsourced research, data analysis, drug discovery, EU-Citizen Science, European Commission, Francisco Javier Lobo Cabrera, global citizen-science initiative, Horizon 2020, Horizon 2020 programme, image repository, Jmol, Jmol software, José Antonio Prado-Bassas, María Ángeles García-Rosado Delgado, molecular visualization, Mosaic Q pattern, novel 3D protein structural pattern, Pablo de Olavide University, protein 3D structure, protein architecture, protein data analysis, protein research, protein structure, proteins, Proteins Mosaic Q, scientific crowdsourcing, SciStarter, stochastic simulations, structural biology, structural patterns in proteins, University of Seville
(IN BRIEF) A review published in Nature Reviews Neurology highlights how researchers at the Luxembourg Institute of Health, in collaboration with the University of Luxembourg, are advancing brain tumour research through the development of organoid models. These three-dimensional, patient-derived structures … Read the full press release
Posted in Business, Education, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged Anna Golebiewska, brain tumours, cancer research, drug screening, Luxembourg Institute of Health, Luxembourg Institute of Health Researchers Outline New Advances in Organoid-Based Brain Cancer Research and Drug Screening, Luxembourg Institute of Health Showcases Organoids as a Promising Tool for Personalised Brain Tumour Treatment Strategies, molecular profiling, Nature Reviews Neurology, neuro-oncology, NORLUX Neuro-Oncology Laboratory, organoids, patient-derived models, personalised treatment, precision medicine, tumour heterogeneity, University of Luxembourg
(IN BRIEF) Proteins Mosaic Q is a global citizen-science initiative that invites volunteers to help confirm a newly identified structural pattern in the three-dimensional architecture of proteins. The project focuses on how amino acids cluster according to their chemical families, … Read the full press release
Posted in European Union, Healthcare, Pharma & Biotech, Science, Spain, Technology
Tagged 3D protein-structure snapshots, 3D structure of proteins, a citizen-science project, amino acid clustering, amino acids, Bioinformatics, biology, biomolecules, citizen science, citizen-science platforms, collaborative science, computational biology, EU-Citizen Science, European Commission, Francisco Javier Lobo Cabrera, global citizen-science initiative, Horizon 2020 programme, image repository, Jmol, Jmol software, José Antonio Prado-Bassas, María Ángeles García-Rosado Delgado, molecular visualization, novel 3D protein structural pattern, Pablo de Olavide University, protein 3D structure, protein architecture, protein data analysis, protein research, protein structure, proteins, Proteins Mosaic Q, scientific crowdsourcing, SciStarter, structural biology, structural patterns in proteins, University of Seville
(IN BRIEF) AstraZeneca has received approval from the European Commission for the use of Imfinzi (durvalumab) in combination with FLOT chemotherapy as a perioperative treatment for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The approval … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Oncology Portfolio as EU Approves Imfinzi-Based Regimen for Early Gastric and GEJ Cancer, cancer immunotherapy approval, Committee for Medicinal Products for Human Use, Dave Fredrickson, durvalumab, EU cancer treatment authorization, European Commission, event-free survival, FLOT chemotherapy, Gastric Cancer Treatment, gastroesophageal junction cancer, Imfinzi, immunotherapy oncology, Josep Tabernero, MATTERHORN trial, MATTERHORN Trial Results Lead to EU Approval of Imfinzi Immunotherapy for Early-Stage Gastric Cancer Treatment, oncology clinical trials, overall survival, Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology
(IN BRIEF) Scientists at the Institute of Cancer Research in London are contributing to an international clinical trial evaluating THEO-260, an experimental oncolytic immunotherapy designed to treat platinum-resistant ovarian cancer. The trial, known as OCTOPOD-IV, is being supported by €8 … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alan Melcher, cancer associated fibroblasts CAF, Cancer Center Clínica Universidad de Navarra, cancer immunotherapy development, Catalan Institute of Oncology, Horizon Europe funding, ICR cancer research, Institute of Cancer Research Joins International Trial of Novel Oncolytic Immunotherapy for Platinum-Resistant Ovarian Cancer, Institute of Cancer Research London, International Cancer Research Collaboration Advances Clinical Study of THEO-260 Immunotherapy for Hard-to-Treat Ovarian Tumours, Margaret Duffy, OCTOPOD IV clinical trial, oncolytic virus therapy, ovarian cancer research, platinum resistant ovarian cancer, Princess Margaret Cancer Centre, THEO 260 oncolytic immunotherapy, Theolytics biotechnology, translational cancer research, tumour microenvironment research
(IN BRIEF) Almirall has opened new offices in Shanghai to strengthen its collaboration with Chinese partners and expand innovation in medical dermatology. The new Shanghai presence will support research partnerships, business development and technology collaborations that complement the company’s main … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Spain, Technology
Tagged Almirall, Almirall Expands Medical Dermatology Innovation Network with Shanghai Office and Strategic Partnerships in China, Almirall Shanghai Pharmaceutical Consulting Co Ltd, alopecia areata treatment research, atopic dermatitis therapy development, Barcelona Sant Feliu de Llobregat R&D centre, Carlos Gallardo, Cutia pharmaceutical partnership, dermatology pharmaceutical innovation, global dermatology drug development, hidradenitis suppurativa research, IL-2muFc interleukin 2 mutant fusion protein, medical dermatology research pipeline, sarecycline acne treatment China, Shanghai Jing’an district, Simcere Pharmaceutical Group, Sinomune pharmaceutical collaboration, Spain China pharmaceutical cooperation, topical finasteride androgenetic alopecia China, Zhou Gaobo
(IN BRIEF) GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. The therapy is … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Italy, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alfasigma, Alfasigma secures worldwide rights to linerixibat as GSK advances strategy in liver disease innovation, cholestatic pruritus therapy, drug development partnership, EU UK regulatory review, FDA approval process, Francesco Balestrieri, GLISTEN Phase III trial, global pharmaceutical collaboration, GSK, GSK partners with Alfasigma to advance linerixibat therapy for patients with primary biliary cholangitis, hepatology treatments, IBAT inhibitor, linerixibat, liver disease innovation, orphan drug designation, PBC treatment, pharmaceutical licensing agreement, primary biliary cholangitis, rare liver diseases, Tony Wood
(IN BRIEF) Sanofi announced that its Board of Directors will propose the appointment of Orange CEO Christel Heydemann as an independent director during the company’s Annual General Meeting scheduled for April 29, 2026. At the same meeting, shareholders will also … Read the full press release
Posted in Business, Financial, France, Industrial, Investment, Management, Pharma & Biotech, Science, Technology
Tagged Alcatel, Alcatel-Lucent, Annual General Meeting April 2026, Belén Garijo, board leadership diversity, Christel Heydemann, Christophe Babule, corporate governance, digital transformation leadership, diversity in science and technology, Ecole Nationale des Ponts et Chaussées, École polytechnique, executive leadership Europe, Frédéric Oudéa, French National Order of Merit, global pharmaceutical company governance, independent director appointment, Industrial Transformation, Jean-Paul Kress, Legion of Honor France, Nomination Governance and CSR Committee, Orange Group, Patrick Kron, Sanofi, Sanofi Board Announces Governance Updates Including Proposed Appointment of Christel Heydemann and Departure of Patrick Kron, Sanofi Board of Directors, Sanofi Moves to Strengthen Board Expertise with Proposed Addition of Orange CEO Christel Heydemann, Sanofi Prepares Governance Changes Ahead of April 2026 Annual General Meeting with Proposed Board Appointment, Schneider Electric
(IN BRIEF) The Academy of Medical Sciences has launched a UK Medical Science Careers Taskforce to address growing challenges affecting the country’s medical research workforce. Co-chaired by Professor Sir Munir Pirmohamed of the University of Liverpool and Dr Tony Wood … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 10 Year Health Plan for England, Academy of Medical Sciences, Academy of Medical Sciences Launches UK Taskforce to Strengthen Medical Science Career Pathways, AI and data science in healthcare, Andrew Morris, biomedical research careers UK, clinical academic workforce shortage, GlaxoSmithKline, Life Sciences Sector Plan UK, medical research workforce development, medical science career pathways, MedTech industry workforce, New UK Medical Science Careers Taskforce Led by University of Liverpool and Industry Leaders to Address Workforce Gaps, NHS research workforce, pharmaceutical research careers, Professor Sir Munir Pirmohamed, Tony Wood, UK health research policy, UK life sciences sector, UK Medical Science Careers Taskforce, University of Liverpool
(IN BRIEF) Sanofi has obtained orphan drug designation in Japan for rilzabrutinib as a treatment for IgG4-related disease, a rare immune-mediated condition with limited treatment options. The designation from Japan’s Ministry of Health, Labour and Welfare is supported by positive … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged Bruton tyrosine kinase inhibitor, BTK inhibitor, IgG4-RD, IgG4-related disease, immune thrombocytopenia, immune-mediated diseases, ITP, MHLW, Ministry of Health Labour and Welfare Japan, orphan drug designation, phase 2 clinical trial NCT04520451, rare disease treatment, rare diseases, rheumatology, RILIEF phase 3 study NCT07190196, rilzabrutinib, Sanofi, Sanofi Expands Global Regulatory Recognition of Rilzabrutinib for Rare Immune Mediated Diseases, Sanofi Secures Japanese Orphan Drug Status for Rilzabrutinib Following Positive Clinical Study Results, SCD, sickle cell disease, wAIHA, warm autoimmune hemolytic anemia
(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, … Read the full press release
Posted in Berlin, Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Actinium-225, alpha emitters, Berlin development laboratory, biotechnology collaboration, DARPin technology, Eckert & Ziegler and Molecular Partners Collaborate on DARPin-Based Radiopharmaceutical Development for Targeted Cancer Therapy, Eckert & Ziegler Expands Radiopharmaceutical Development Capabilities Through Partnership with Molecular Partners, Eckert & Ziegler SE, Harald Hasselmann, isotope technology, Lutetium-177, Molecular Partners AG, nuclear medicine, oncology therapeutics, Radio-DARPins, radiochemistry, radiolabeled therapeutics, radiopharmaceuticals, targeted cancer therapy, TecDAX
(IN BRIEF) Researchers at The Institute of Cancer Research, London have created a next-generation PROTAC degrader that successfully eliminates the cancer-related protein Aurora A while overcoming the hook effect that has limited earlier degraders. The new molecule, CCT400028, demonstrates improved … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged alisertib, Aurora A kinase, Cancer Research UK, cancer therapeutics, CCT400028, chemical probes, Children’s Brain Tumour Centre of Excellence CBTCE, Gary Newton, glioma, hook effect, Institute of Cancer Research Develops Advanced Aurora A PROTAC Degrader That Overcomes Hook Effect and Improves Stability, Institute of Cancer Research London, Journal of Medicinal Chemistry, leukaemia, Lindsay Evans, Neuroblastoma, New Aurora A Degrader from Institute of Cancer Research Demonstrates Improved Selectivity and Reliability in Cancer Studies, paediatric cancers, Paul Workman, PROTAC, protein degradation technology, targeted protein degradation, University of Kiel
(IN BRIEF) Empa researcher Inge Herrmann has secured 8 million Swiss francs in funding from the Werner Siemens Foundation to develop SonoGuard, a novel system designed to detect and treat complications after surgery. The five-year project aims to create an … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Balgrist University Hospital, Benjamin Suter, biomedical research, Empa, ETH Zurich, gastrointestinal surgery, hydrogel patch, implant infections, Inge Herrmann, medical technology, postoperative monitoring, sepsis prevention, SonoGuard, SonoGuard Project at Empa Receives Major Funding to Develop Early Warning System for Surgical Complications, surgical complications, Switzerland research funding, ultrasound contrast agent, University of Zurich, Werner Siemens Foundation, Werner Siemens Foundation Supports Empa SonoGuard Project for Early Detection of Surgical Complications
(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 35Pharma, activin signalling inhibitor, biotechnology acquisition, CANADA, cardiopulmonary diseases, clinical trials, drug development, GSK, GSK Targets Next Generation Pulmonary Hypertension Treatments with Acquisition of 35Pharma, GSK to Acquire 35Pharma for 950 Million Dollars to Strengthen Pulmonary Hypertension Drug Pipeline, HS235, Ilia Tikhomirov, PH-HFpEF, pharmaceutical industry, pulmonary arterial hypertension PAH, pulmonary hypertension, Respiratory Immunology and Inflammation portfolio, Tony Wood
(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Switzerland
Tagged antibiotic development, antimicrobial resistance, ASPR, BARDA, Basilea Advances Antibiotic Pipeline with BARDA Funding for Oral Beta Lactam Combination Therapy, Basilea Pharmaceutica, Basilea Receives USD 6 Million BARDA Funding to Advance Development of Oral Antibiotic for Drug Resistant Urinary Infections, beta lactam beta lactamase inhibitor, ceftibuten ledaborbactam etzadroxil, complicated urinary tract infections cUTI, Cresemba®, David Veitch, FDA Fast Track designation, multidrug resistant bacteria, pyelonephritis, Qualified Infectious Disease Product QIDP, US Department of Health and Human Services, Zevtera®
(IN BRIEF) The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several other retinal disorders. The therapy has demonstrated comparable efficacy and safety to … Read the full press release
Posted in Business, European Union, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged access to medicines, Afqlir, Basel Switzerland, biosimilars Europe, choroidal neovascularization, diabetic macular edema, diabetic retinopathy, EU commercialization rights, European Commission approval, eye disease treatment, Lucentis reference medicine, lupin, neovascular age-related macular degeneration, ophthalmology treatments, pharmaceutical partnership, ranibizumab biosimilar, Ranluspec, retinal vein occlusion, Sandoz, Sandoz and Lupin Advance European Market Entry for Ranluspec Following Regulatory Clearance, Sandoz Secures European Approval for Ranluspec to Expand Access to Biosimilar Treatment in Retinal Diseases
(IN BRIEF) Aalborg University has joined forces with Aarhus University and quantum technology company Kvantify in the ODAQS project, a DKK 17.4 million initiative funded by Innovation Fund Denmark to make quantum computing more practical for pharmaceutical research. The project … Read the full press release
Posted in Artificial Intelligence (AI), Denmark, Education, Healthcare, Management, News, Pharma & Biotech, Science, Society, Technology
Tagged Aalborg University, Aarhus University, Allan Grønlund, Christian Schilling, Danish research collaboration, drug discovery, Grand Solutions programme, Healthcare Innovation, Innovation Fund Denmark, Innovation Fund Denmark Backs Quantum Software Development to Unlock Faster and More Cost Efficient Pharmaceutical Research, Jaco van de Pol, Kim Guldstrand Larsen, Kvantify, New Collaboration Between Universities and Kvantify Targets Software Breakthroughs for Real World Quantum Computing, ODAQS project, optimized compilation, pharmaceutical research, programming languages, quantum algorithms, quantum chemistry, quantum computing, quantum software stack, quantum technology development, reinforcement learning, software verification
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?